Breast Cancer Research

official impact factor 5.79

Open Access Highly Access Research article

Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer

Mark R Pickard1, Andrew R Green2, Ian O Ellis2, Carlos Caldas3, Vanessa L Hedge1, Mirna Mourtada-Maarabouni1 and Gwyn T Williams1*

Author Affiliations

1 Institute for Science and Technology in Medicine and School of Life Sciences, Keele University, Huxley Building, Keele ST5 5BG, UK

2 Division of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals, Derby Road, Nottingham NG7 2UH, UK

3 Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 0RE, UK

For all author emails, please log on.

Breast Cancer Research 2009, 11:R60 doi:10.1186/bcr2350

Published: 11 August 2009

Abstract

Introduction

Programmed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to the appearance of the therapy-resistant cancer cells that produce clinical relapse. Functional expression cloning in two independent laboratories has identified Finkel–Biskis–Reilly murine sarcoma virus-associated ubiquitously expressed gene (Fau) as a novel apoptosis regulator and candidate tumour suppressor. Fau modifies apoptosis-controller Bcl-G, which is also a key target for candidate oncoprotein maternal embryonic leucine zipper kinase (MELK).

Methods

We have used RNA interference to downregulate Fau and Bcl-G expression, both simultaneously and independently, in breast cancer cells in vitro to determine the importance of their roles in apoptosis. Expression of Fau, Bcl-G and MELK was measured by quantitative RT-PCR in breast cancer tissue and in matched breast epithelial tissue from the same patients. Expression data of these genes obtained using microarrays from a separate group of patients were related to patient survival in Kaplan–Meier analyses.

Results

siRNA-mediated downregulation of either Fau or Bcl-G expression inhibited apoptosis, and the inhibition produced by combining the two siRNAs was consistent with control of Bcl-G by Fau. Fau expression is significantly reduced in breast cancer tissue and this reduction is associated with poor patient survival, as predicted for a candidate breast cancer tumour suppressor. In addition, MELK expression is increased in breast cancer tissue and this increase is also associated with poor patient survival, as predicted for a candidate oncogene. Bcl-G expression is reduced in breast cancer tissue but decreased Bcl-G expression showed no correlation with survival, indicating that the most important factors controlling Bcl-G activity are post-translational modification (by Fau and MELK) rather than the rate of transcription of Bcl-G itself.

Conclusions

The combination of in vitro functional studies with the analysis of gene expression in clinical breast cancer samples indicates that three functionally interconnected genes, Fau, Bcl-G and MELK, are crucially important in breast cancer and identifies them as attractive targets for improvements in breast cancer risk prediction, prognosis and therapy.